FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 奇士達控股有限公司(於開曼群島註冊成立之有限公司) 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06918 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.001 | HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.001 | HKD | | 5 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號︰269） 更改開曼群島之註冊辦事處地址 中國資源交通集團有限公司(「本公司」)董事會(「董事會」)謹此宣佈, 於本公告 日期，本公司於開曼群島之註冊辦事處地址已更改為： JTC (Cayman) Limited P.O. Box 30745 60 Nexus Way, 6th Floor, Camana Bay, Grand Cayman KY1-1203, Cayman Islands 承董事會命 中國資源交通集團有限公司 CHINA RESOURCES AND TRANSPORTATION GROUP LIMITED 中國資源交通集團有限公司 高志平 聯席主席 香港，2026年3月2日 於本公佈日期，本公司董事會成員包括五名執行董事陸志明先生、高志平先生、 姜濤先生、段景泉先生及王剛先生；以及三名獨立非執行董事井寶利先生、薛寶 忠先生及黃春蓮女士。 - ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： HKD 4,000,000,000 FF ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： HKD ...

Group 1 - The company Guodi Technology (002694) announced that its net assets are expected to be negative by the end of 2025, which may lead to a delisting risk warning for its stock [1][3] - On February 2, the company's stock price hit the daily limit down, closing at 3.33 yuan per share [1] - Guodi Technology's 2025 performance forecast indicates a projected net loss attributable to shareholders of 300 million to 577 million yuan, with a non-recurring net profit loss of 63.21 million to 123 million yuan [3] Group 2 - The anticipated negative net assets are primarily due to provisions for pending litigation losses, estimated between 280 million to 410 million yuan [3] - The company is attempting to improve its sales strategies, product structure, and expand its dealer network to enhance gross profit margins, while also focusing on internal management and cost control [3] - Guodi Technology has faced significant litigation costs, including a case with Zhejiang Jinggong Steel Structure Group, which has resulted in a cumulative provision loss exceeding 287 million yuan [5] Group 3 - The company has diversified into the cultural tourism sector, investing approximately 1 billion yuan in the Alxa Desert Dream Car Aviation Park project, but this has not yielded the expected returns [4] - Guodi Technology is currently involved in multiple legal disputes, including a second-instance case with Zhejiang Jinggong and a construction contract dispute with Ningxia Construction Group, which has led to additional provisions totaling 109.45 million yuan [5][6] - The company has engaged a professional legal team to address these ongoing legal challenges [6]

Group 1 - The core achievement of Chery Group in January 2026 is a total sales volume exceeding 200,000 units, reaching 200,269 vehicles [1] - The sales of new energy vehicles reached 52,131 units [1] - Export volume increased by 48.1% year-on-year, totaling 119,605 units [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) is expected to turn a profit in 2025, with net profit attributable to shareholders projected between 16 million to 23 million yuan, marking a significant turnaround from losses in the previous year [1] Financial Performance - The company anticipates a total profit growth of 107.53% to 111.30% year-on-year, with net profit attributable to shareholders expected to increase by 120.43% to 129.37% [1] - Revenue is projected to be between 250 million to 290 million yuan [1] Factors Influencing Profit Changes - The company is focusing on international development to counteract domestic drug price declines, leading to steady growth in export sales and advancements in overseas R&D projects [1] - The approval of the U.S. registration application for injectable paclitaxel (albumin-bound) is expected to drive significant revenue growth following its rapid sales post-approval [1] - The absence of fair value loss from Zhongrong Trust financial products, which impacted the previous year's results, and a reduction in asset impairment losses have also contributed to the turnaround [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) has been recognized as a high-tech enterprise in Ningbo for the first batch of 2025, which will provide tax benefits for the next three years [1] Group 1: Company Recognition - Ningbo Shuangcheng Pharmaceutical Co., Ltd., a subsidiary of Hainan Shuangcheng Pharmaceutical Co., Ltd., has been certified as a high-tech enterprise by the Ningbo Municipal High-tech Enterprise Recognition Management Work Leading Group [1] - The high-tech enterprise certificate number is GR202533101446, issued on December 8, 2025, and is valid for three years [1] Group 2: Tax Benefits - Following the recognition, Ningbo Shuangcheng will enjoy a preferential corporate income tax rate of 15% for three consecutive years, as per the relevant provisions of the Corporate Income Tax Law of the People's Republic of China [1] Group 3: Impact on Financial Performance - The recognition will not have an impact on the company's current operating performance [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： H ...

Group 1 - The core point of the article is that *ST Shuangcheng (002693.SZ) has received FDA approval for its injectable bortezomib ANDA product [1] Group 2 - The company announced the FDA approval on its investor interaction platform [1]